Melbourne – September 08, 2026 -- Dimerix Limited (ASX: DXB) has secured non-dilutive loan facility agreements worth up to A$34 million with a syndicate of Australian and U.S. lenders, expanding on its previously announced A$10 million SKIPTAN facility.
Dimerix locks in A$34 million loan facility from Australian, U.S. lenders
The new terms are substantially consistent with the earlier SKIPTAN agreement, with minor amendments made to standardise conditions across all lenders. The structure gives Dimerix the option to expand total commitments to A$50 million on or before March 31, 2027, though the company currently has no plans to draw on that additional capacity.
Company draws only 50% of committed funds to limit shareholder dilution
Dimerix has elected to initially drawdown just half of the committed facility, judged sufficient to complete its currently planned clinical activities. The initial 50% tranche is expected to be received in September 2026, with the remainder available at the company's discretion before the March 2027 deadline.
Funding secures completion of ACTION3 Phase 3 trial and DMX-652 AKI program
Combined with existing cash reserves, the facility funds Dimerix through completion of the fully recruited global ACTION3 Phase 3 trial of DMX-200 in focal segmental glomerulosclerosis (FSGS), as well as the Phase 2 trial of DMX-652 in acute kidney injury (AKI) following cardiac surgery. Dimerix expects to repay the facility through future licensee milestone payments, potential new license fees, or capital market access.
Five commercial partners have delivered A$81 million upfront, A$237 million in milestones pending
Dimerix has secured five commercial partners across major markets, which have generated A$81 million in upfront payments to date and created the opportunity for a further A$237 million in development milestone payments ahead of commercial launch.
CEO Dr Nina Webster said the facility reflects growing lender confidence in Dimerix's clinical programs and allows the company to execute planned development activities without diluting shareholders. DMX-200, a CCR2 antagonist, is protected by patents until 2032, with pending applications that could extend protection to 2042, alongside Orphan Drug Designation in the U.S., Europe, UK and Japan. More than 40,000 people are estimated to be living with FSGS in the United States alone, with no therapies currently approved specifically for the condition.